**Supplementary Figure 1.** LVEF for patients with HER2-positive early-stage breast cancer before and after neoadjuvant treatment with CT-P6 or RTZ.

**A picture containing table

Description automatically generated**

CI, confidence interval; HER2, human epidermal growth factor receptor 2; LVEF, left ventricular ejection fraction; RTZ, reference trastuzumab.

**Supplementary Figure 2** Change in LVEF over time for patients with HER2-positive metastatic breast cancer who received palliative treatment with CT-P6 or RTZ.

****

HER2, human epidermal growth factor receptor 2; LVEF, left ventricular ejection fraction;RTZ, reference trastuzumab.